Prothena (PRTA)
(Delayed Data from NSDQ)
$20.81 USD
+0.60 (2.97%)
Updated May 31, 2024 04:00 PM ET
After-Market: $20.78 -0.03 (-0.14%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Brokerage Reports
0 items in cart
Prothena Corporation plc [PRTA]
Reports for Purchase
Showing records 321 - 331 ( 331 total )
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY.
Provider: Roth Capital Partners, Inc.
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Initiating Coverage with OUTPERFORM Rating, $18 Price Target.
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
Initiating Coverage with OUTPERFORM Rating, $18 Price Target
Provider: WEDBUSH SECURITIES INC.
Analyst: MARAI C
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Prothena Corporation plc
Industry: Medical - Biomedical and Genetics
We launch coverage with a Buy and a $16 target.
Provider: Roth Capital Partners, Inc.
Analyst: HAZLETT R